REG - Immupharma PLC - Notice of AGM & Annual Report & Accounts

ImmuPharmaAnnouncement

01/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220601:nRSA4784Na&default-theme=true

RNS Number : 4784N  Immupharma PLC  01 June 2022

 

 

 

 

RNS:
RELEASE
1 JUNE 2022

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Notice of AGM & Annual Report & Accounts

 

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development
company, confirms that the Notice of Annual General Meeting ("AGM") has been
posted to shareholders. The Annual Report and Accounts for the year ended 31
December 2021 will be posted to shareholders on 6 June 2022.

 

These documents will be available shortly, in electronic form, for download on
the Company's website www.immupharma.co.uk (http://www.immupharma.co.uk) .

 

ImmuPharma's AGM will be held on Tuesday 28 June 2022 @ 10.30am (BST) at: One
Bartholomew Close, London, EC1A 7BL.

Ends

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )  + 44 (0) 207 206 2650

 Tim McCarthy, Chairman and Chief Executive

 Lisa Baderoon, Head of Investor Relations                         + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                           +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                          +44 (0) 203 815 8880

 Patrick Claridge, John Howes, Bob Pountney

 SI Capital (Joint Broker)                                         +44 (0) 1483 413500

 Nick Emerson

 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases, metabolic
diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a
first-in class autophagy immunomodulator which is in Phase 3 for the treatment
of lupus and preclinical analysis suggest therapeutic activity for many other
autoimmune diseases that share the same autophagy mechanism of action.
ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive
licence and development agreement and trademark agreement for Lupuzor™ to
fund a new international Phase 3 trial for Lupuzor™ and commercialise in the
US.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSFLFLAEDILVIF